Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Stifel, Morgan Stanley bullish on newly public Contineum | 2 | Seeking Alpha | ||
09.04. | Contineum Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.04. | Contineum Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
05.04. | Contineum Therapeutics stock slides 10% following $110M IPO | 1 | Seeking Alpha | ||
05.04. | J&J-Partnered Contineum Corrals $110M From IPO for Clinical Trials in Fibrosis & MS | 27 | MedCity News | ||
05.04. | CTNM Stock: 7 Things to Know as Contineum Therapeutics Starts Trading Today | 1 | InvestorPlace | ||
05.04. | Contineum lowers expectations for $110M IPO as J&J-allied biotech goes public | 13 | FierceBiotech | ||
05.04. | Neuro and inflammation biotech Contineum Therapeutics prices downsized IPO at $16, the low end of the range | 1 | Renaissance Capital | ||
05.04. | Contineum Therapeutics prices initial offering at $16 per share | 1 | Seeking Alpha | ||
05.04. | Contineum Therapeutics Prices IPO Of About 6.88 Mln Shares At $16.00/shr | 1 | RTTNews | ||
05.04. | Contineum Therapeutics, Inc.: Contineum Therapeutics Announces Pricing of Initial Public Offering | 87 | GlobeNewswire (Europe) | SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule... ► Artikel lesen | |
02.04. | Contineum Therapeutics, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
02.04. | IPO Roundup: Rubrik, Contineum Therapeutics, and more | 1 | Seeking Alpha | ||
01.04. | Contineum Therapeutics Announces Initial Public Offering Of Class A Common Stock | 237 | AFX News | WASHINGTON (dpa-AFX) - Contineum Therapeutics, Inc. said it is offering 8.8 million shares of Class A common stock. It is currently estimated that the initial public offering price per share... ► Artikel lesen | |
01.04. | Neuro and inflammation biotech Contineum Therapeutics sets terms for $150 million IPO | 1 | Renaissance Capital | ||
01.04. | Contineum Therapeutics Announces 8.8M Share IPO at $16-$18/sh | 1 | Investing.com | ||
01.04. | Contineum Therapeutics, Inc. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
19.03. | MS drug developer Contineum files for $150M IPO | 1 | Seeking Alpha | ||
18.03. | With MS & Fibrosis Trials Planned, J&J-Partnered Contineum Now Preps for IPO | 4 | MedCity News | ||
18.03. | J&J-allied Contineum files for IPO to take fight to BMS, Roche and more | 31 | FierceBiotech |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MORPHOSYS | 65,60 | -0,91 % | EQS-PVR: MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: MorphoSys AG
MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
25.04.2024 / 16:00 CET/CEST
Veröffentlichung... ► Artikel lesen | |
EVOTEC | 9,870 | +1,33 % | Allianz, Andritz, CureVac, Deutsche Telekom, Evotec - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
QIAGEN | 39,790 | +1,82 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 41,950 | -10,44 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 4,148 | +170,76 % | CytomX-Aktie +259%: Top-Empfehlung dreht völlig durch! | Mit der Aktie des Biotech-Unternehmens CytomX Therapeutics (WKN: A14158) knallt einer unserer Top-Tipps am Mittwoch in der Spitze um +259% von 1,63 US$ bis auf 5,85 US$ in die Höhe - bei absoluten Rekordumsätzen... ► Artikel lesen | |
BIONTECH | 85,30 | +1,97 % | BioNTech: Bringen Sie sich in Sicherheit! | Zahlreiche Nackenschläge müssen heute die Anteilseigner von BioNTech hinnehmen. Denn die Aktie stürzt mit einem Minus von rund zwei Prozent regelrecht ab. Ein Anteilsschein ist damit nur 80,85 EUR wert.... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,470 | +1,56 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
MODERNA | 112,36 | +8,73 % | Verhaltene Impfstoff-Nachfrage: BioNTech-Konkurrent Moderna: Umsatz bricht um 91 Prozent ein | © Foto: picture alliance / Geisler-Fotopress | Christoph Hardt/Geisler-FotopresTrotz erneut gesunkener Erlöse hat Biotech-Unternehmen Moderna die Erwartungen der Analysten übertreffen können. Dennoch... ► Artikel lesen | |
CABALETTA BIO | 12,450 | +0,32 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
MERRIMACK PHARMACEUTICALS | 15,010 | +0,23 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
DYNE THERAPEUTICS | 25,310 | -2,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
BEAM THERAPEUTICS | 22,400 | +3,04 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
ARCELLX | 51,80 | -0,69 % | Arcellx, Inc.: Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights | -- Expanded strategic partnership with Kite --
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory... ► Artikel lesen | |
BB BIOTECH | 43,100 | +2,13 % | Ihre wichtigsten Termine: Zahlen-Update von: Michelin, Totalenergies, SGS, BB Biotech, Natwest & Südzucker | © Foto: Fabian Sommer - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
HUMACYTE | 4,320 | -1,82 % | Humacyte, Inc: Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update | -Biologics License Application (BLA) for HAV Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately... ► Artikel lesen |